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Alzheimer’s disease cerebrospinal fluid
biomarkers are not influenced by gravity
drip or aspiration extraction methodology
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Kelly K. Pertile1, Rebecca L. Rumble1, Brett O. Trounson1, Sarah Maher2, Francis Mooney2, Maree Farrow3,
Kevin Taddei4,5, Stephanie Rainey-Smith4,5, Simon M. Laws4,5, S. Lance Macaulay7, William Wilson8,
David G. Darby1*, Ralph N. Martins4,5, David Ames9, Steven Collins6, Brendan Silbert2, Colin L. Masters1,
James D. Doecke7,8 and the AIBL Research Group
Abstract
Introduction: Cerebrospinal fluid (CSF) biomarkers, although of established utility in the diagnostic evaluation of
Alzheimer’s disease (AD), are known to be sensitive to variation based on pre-analytical sample processing. We
assessed whether gravity droplet collection versus syringe aspiration was another factor influencing CSF biomarker
analyte concentrations and reproducibility.
Methods: Standardized lumbar puncture using small calibre atraumatic spinal needles and CSF collection using
gravity fed collection followed by syringe aspirated extraction was performed in a sample of elderly individuals
participating in a large long-term observational research trial. Analyte assay concentrations were compared.
Results: For the 44 total paired samples of gravity collection and aspiration, reproducibility was high for biomarker
CSF analyte assay concentrations (concordance correlation [95%CI]: beta-amyloid1-42 (Aβ42) 0.83 [0.71 - 0.90]), t-tau
0.99 [0.98 - 0.99], and phosphorylated tau (p-tau) 0.82 [95 % CI 0.71 - 0.89]) and Bonferroni corrected paired sample
t-tests showed no significant differences (group means (SD): Aβ42 366.5 (86.8) vs 354.3 (82.6), p = 0.10; t-tau 83.9
(46.6) vs 84.7 (47.4) p = 0.49; p-tau 43.5 (22.8) vs 40.0 (17.7), p = 0.05). The mean duration of collection was
10.9 minutes for gravity collection and <1 minute for aspiration.
Conclusions: Our results demonstrate that aspiration of CSF is comparable to gravity droplet collection for AD
biomarker analyses but could considerably accelerate throughput and improve the procedural tolerability for
assessment of CSF biomarkers.
Introduction
In 2011, proceedings from the National Institute on
Aging - Alzheimer’s Association workgroups on diagnos-
tic guidelines for Alzheimer’s disease (AD) recommended
the addition of biomarkers as an important component of
diagnosis [1]. Neuroimaging and cerebrospinal fluid (CSF)
sampling are able to identify individuals with high likeli-
hood of AD pathology. Amyloid-PET imaging can detect
neocortical accumulation of fibrillary amyloid up to
30 years prior to first symptoms of AD [2] and CSF bio-
marker assays demonstrate abnormalities at least 20 years
prior to the expected age of onset in dominantly inherited
AD pedigrees [3].
The CSF in established AD is characterized by a de-
crease in Aβ42 and increases in total tau (t-tau) and tau
phosphorylated at threonine 181 (p-tau). The diagnostic
performance of these CSF biomarkers to discriminate
AD from non-demented older individuals is high, with
sensitivity and specificity figures of 80 %–90 % [4]. In
addition to the high sensitivity and specificity, CSF ana-
lysis has several advantages as a biomarker of choice.
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Lumbar puncture is easy to perform, does not require
expensive and sophisticated equipment and does not re-
quire the use of expensive radio-ligands. Furthermore, it
provides a simple fluid matrix that allows AD biomarker
interrogation and potential additional evaluation of other
analytes, as well as routine biochemistry and micros-
copy. Herskovits and Growden have called for the wide-
spread establishment of lumbar puncture clinics to
enable the routine use of CSF both for diagnosis of AD
and the monitoring of the CSF response to therapeutic
trials [5]. Adverse events with lumbar puncture (LP) are
low with technical optimization [6]. No major complica-
tions from LPs conducted in memory clinics were re-
ported in 1,089 patients, and mild post-LP headaches
were reported in only 28 (2.6 %) of the patients [7].
Considerable variability in absolute concentrations of
AD biomarkers has been reported by different centers
using the same assay, leading to different cutoff values
[8]. A quality control program has been established to
decrease variability across centers [9]. An important ad-
junct to this has been the recommendation of systematic
pre-analytical handling by the Alzheimer’s Biomarkers
Standardization Initiative (ABSI) [10]. This consensus
statement outlined how pre-analytical management of
CSF should be undertaken in order to standardize all as-
pects of sample handling until the point of analysis.
Most of the recommendations were based on expert
opinion rather than evidence. A commitment was made
to provide evidence for unanswered questions such as
the effect of tube composition on assay results.
A key issue which was not considered in the ABSI
statement was the methodology for CSF collection. Dur-
ing LP CSF can be collected by allowing it to drip into
the collecting tube (gravity drip) or by aspiration with a
syringe (syringe aspiration). Proponents of gravity drip
maintain that when a syringe is used to aspirate CSF, the
extra surface area of the syringe (even when it is poly-
propylene) may adsorb analytes and thus influence assay
results, while others believe that if a suitable polypropyl-
ene syringe is used, the resulting assays for the bio-
markers of AD will not be affected. Consequently, some
investigators use gravity flow in the belief that this will
minimize this effect [11]. Gravity can also be used to fill
the manometer tubing for measuring CSF pressure and
then emptying the fluid in the tubing into polypropylene
containers [7] (personal communication Kaj Blennow).
Other investigators routinely use syringe aspiration.
The method of CSF collection is an important issue
because taking volumes of CSF greater than 10 mL
by gravity drip is time consuming and can be uncom-
fortable for the participant. The time taken could be
an impediment to routine CSF sampling if higher
throughput is desired for both diagnosis and monitor-
ing of AD.
To investigate potential effects of collection method-
ology we compared gravity drip collection (directly from
the needle) with negative pressure aspiration using a
polypropylene syringe when assaying AD CSF biomarker
concentrations, during the same lumbar puncture for
each subject. All other pre-analytical and analytical as-
pects of the procedures were identical. We hypothesized




A total of 54 participants (38 healthy controls (HC),
eight with mild cognitive impairment (MCI) and eight
with AD) from the Australian Imaging Biomarker and
Lifestyle (AIBL) study of aging were evaluated using
standardized LP. Description of the psychometric test
battery and characterization of AIBL participants at
baseline has been reported previously [12]. All proce-
dures were carried out with institutional human ethics
approval (St Vincent’s Hospital, Fitzroy, Victoria, 3065,
Australia) and participant/carer informed consent.
Lumbar puncture
CSF was collected by LP in the morning from overnight
fasted participants using protocols aligned with the ABSI
[10]. All LPs were performed using a strictly aseptic tech-
nique (gloves, gowns, masks and sterile draping) with the
subjects in the sitting position. The LP was attempted
using a Temena (Polymedic®, EU, temena.com) spinal
needle micro-tip (22/27G x 103 mm) (CAT 21922–27). If
there was difficulty using this fine needle, a RapID set pen-
cil point spinal needle, 25G (Smiths Medical ASD, Inc,
Keene, NH, USA) was used. The procedure was con-
strained by the AIBL CSF collection protocol which re-
quired gravity drip collection, so all aspiration samples
for this study were taken after gravity drip collection. Up
to 6 mLs of CSF was initially aspirated for routine micro-
biological and biochemical assessment, as well as concur-
rent studies, after which 8 mLs of CSF was collected by
gravity flow into a 15 mL polypropylene tube (Greneir
Bio-One188271), and placed immediately onto wet ice. At
the completion of the gravity collection, a polypropylene
syringe (BD, North Ryde, NSW, Australia; 2 ml syringe,
ref 302204) was then used to aspirate 2 mL of CSF, which
was then transferred to a polypropylene tube on ice.
Samples were processed within one hour and kept at 4 °C
during transport to the laboratory. The CSF was centri-
fuged (2,000 x g, 4 °C, for ten minutes) and the super-
natant transferred to a new polypropylene tube and
gently inverted. The CSF was then aliquoted in
300 μL volumes into Nunc cryobank polypropylene
tubes (NUN374088). Samples were transferred to dry
ice immediately, and then into liquid nitrogen vapor
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tanks within one hour and only thawed once immedi-
ately before analysis. All participants were contacted
by telephone the following day, and also provided a phone
number if there were any concerns such as headache or
backache.
xMAP biomarker assay
All samples were measured in duplicate using the
AlzBio3 xMAP assay (Innogenetics, N.V. Ghent, Belgium)
according to the included protocol for human CSF Aβ42,
t-tau and p-tau. A total of four assay kits were used to col-
lect the data spread over several days, and all steps were
conducted by the same operator blinded to participant
and CSF collection method, using multichannel pipettes
and a manual wash/vacuum manifold. The same kit
batch-number was used for all assay plates used in the
study and the participant samples were distributed
randomly on the analysis plates. Briefly, all reagents, stan-
dards, controls and samples were brought to room
temperature and vortex-mixed immediately before the
assay. Coated beads were vortexed for three minutes in a
sonicating water bath. All working solutions were diluted
in Milli-Q H2O or supplied diluents according to the kit
instructions. The filter plate was washed once using
225 μL/well of 1x wash buffer and vacuum aspirated im-
mediately before use. A total of 100 μL of bead suspension
(3,000 beads/analyte) was added to each well and the plate
vacuum aspirated. Then 25 μL of the conjugate working
solution was added to each well. A total of 75 μL of stan-
dards, kit and pooled CSF controls and samples were
added to the plate in duplicate. A buffer blank was also in-
cluded. The filter plate was sealed, the bottom of the plate
was dabbed dry and the plate was wrapped in aluminum
foil and incubated on an orbital plate shaker at room
temperature (21–23 °C). The plate was incubated over-
night (at least 14 hours). On the second day, the re-
maining reagents were prepared at room temperature.
The filter plate was aspirated and then washed with
225 μL of 1x wash buffer, three times. A total of 100 μL of
diluted detection reagent was then added to each well and
the plate re-covered in foil for one hour on an orbital plate
shaker. The filter plate was aspirated and washed with
225 μL of 1x wash buffer, three times. Then, 100 μL of
read solution was added to each well and the plate was
finally incubated on an orbital plate shaker for five mi-
nutes covered in foil, at room temperature. The sample
concentrations were then quantified using a Bio-Rad Bio-
plex 200 instrument (Bio-Rad Laboratories, USA) using
5PL logistic regression. The data were fitted to calibration
curves constructed with the median fluorescence values
for each replicate of the standards. Concentrations were
determined by sigmoidal curve fitting. Data from duplicate
sample measurements for each individual’s CSF sample
that had a percentage coefficient of variance (%CV) above
20 % (as recommended by the manufacturer) were dis-
carded and the samples were reanalyzed. For all plates, the
internal standard control duplicate analyses were within
the accepted %CV.
Statistical analysis
Biomarker agreement was assessed using the Concord-
ance Correlation test, with a correlation coefficient close
to 1 representing perfect repeatability. Bland-Altman
plot analysis was conducted to assess agreement between
methods [13]. To determine whether there were any
significant differences in CSF analyte levels between col-
lection methods, the data were analyzed using a paired
sample t-test. A Bonferroni adjustment for multiple
comparisons was used for p-value assessment, with test
results compared against 0.0167 (0.05/3). Statistical ana-
lyses for concordance and sample mean differences were
performed on the original set of 35 samples where the
%CV was less than 20 %, as well as the complete set of
44 samples to determine whether there were any com-
parable differences between the original assay set and
the repeated samples. Linear models between CSF collec-
tion methods were compared using analysis of variance.
Demographic characteristics were assessed using the inde-
pendent samples t-test (age), Chi square analyses (APOEε4
and sex), and Kruskal Wallis tests (Clinical Dementia Rat-
ing (CDR) score and Mini–Mental State Examination
(MMSE) score). All statistical analyses were conducted
using the R software version 3.0.2.
Results
Of the 54 participant samples, 19 failed quality control
for one or more of the multiplexed analytes, with %CV
greater than 20 %. Of these 19, nine samples were re-
run and performed with < 20 % %CVs and were included
in the final analysis using a total of 44 participant sam-
ples. Demographic characteristics of the participants are
shown in Table 1. There was no significant difference in
ages between diagnostic classifications (p = 0.40) or in
the distribution of males and females between clinical
Table 1 Sub-cohort demographics
HC MCI AD p - value
N 31 6 7
Age (years) 71.8 (5.6) 68.3 (4.5) 71.3 (7.1) 0.40
Sex (F%) 58 % 50 % 28 % 0.41
APOEε4 % 19 % 0 % 43 % 0.20
MMSE (median IQR) 29 (1.5) 26 (2) 22 (3) <0.0001
CDR (median IQR) 0 (0) 0.5 (0) 1 (0.25) <0.0001
p–value determined by t-test (age), Chi square analyses (APOEε4 and sex) and
Kruskal-Wallis tests (CDR score and MMSE)
N number, HC health control, MCI mild cognitive impairment, AD Alzheimer’s
disease, APOEε4 apolipoprotein epsilon 4 allele, MMSE Mini–Mental State
Examination, CDR Clinical Dementia Rating, IQR inter-quartile range
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classifications (p = 0.41). There were more APOEε4 car-
riers in the AD group; however, this was not statistically
significant (p = 0.20). As expected, the CDR scale was
significantly higher and the MMSE score significantly
lower in the MCI and AD groups (p < 0.0001). The mean
inter-assay %CV based on the lowest concentration in-
cluded standards was 11.6 % for Aβ42, 7.26 % t-tau, and
11.29 % for p-tau.
Using the complete sample (n = 44), concordance cor-
relations between CSF collection methods showed strong
reproducibility for Aβ42, t-tau, and p-tau (0.83 [95 %
Confidence Interval (CI 0.71 - 0.90], 0.99 [95 % CI 0.98 -
0.99], and 0.82 [95 % CI 0.71 - 0.89], respectively). Redu-
cing the sample to only those with a < 20 % %CV in the
original assay (n = 35) performed similarly compared to
that of the complete sample (Aβ42 0.87 [0.77 - 0.93], t-
tau 0.99 [95 % CI 0.98 - 0.99], and p-tau 0.86 [95 % CI
0.76 - 0.93], respectively). Bland-Altman plots also dis-
played good agreement between the two collection
methods (Fig. 1g, h, i). Table 2 shows the means (SD) for
the three biomarker analyte quantifications.
For the complete cohort, we found no significant dif-
ference (post-correction for multiple comparisons) in
mean Aβ42, t-tau, and p-tau levels between gravity-fed
and aspiration collection methods (Aβ: gravity: 366.5
(86.8) vs aspiration: 354.3 (82.6) p = 0.10; t-tau: gravity:
83.9 (46.6) vs aspiration: 84.7 (47.4), p = 0.49; and p-tau
gravity: 43.5 (22.8) vs aspiration: 40.0 (17.7), p = 0.05).
Analyses of the reduced set (N = 35) found similar re-
sults for each of the analytes (Aβ: gravity: 373.4 (88.0) vs
aspiration: 366.5 (84.8) p = 0.35; t-tau: gravity: 82.8 (48.5)
vs aspiration: 82.3 (48.7), p = 0.64; and p-tau gravity: 41.9
(22.7) vs aspiration: 38.5 (18.6), p = 0.07). Assessment of
intra-classification means showed only small changes in
biomarker level between gravity and aspiration collection
methods; t-tests were not performed due to low sample
size (Table 2, Fig. 1a, b, c). Gravity drip collection versus
aspirated CSF was also plotted differentiating clinical
classification (Fig. 1d, e, f ).
We also classified each participant using the standard-
ized cut-off scores of our laboratory (thresholds for Aβ,
t-tau, and p-tau were 281, 106, and 46, respectively, ±
5 % error) and dichotomized using the 10th and 90th per-
centiles (Li et al., personal communication). Using this
method, only one participant was classified differently
between collection methods (with a 6 % difference be-
tween collection methods).
In four of the 54 participants, it proved difficult to find
the CSF with the fine #27 gauge needles and the 25
gauge pencil point needle was successfully employed. Of
the 54 subjects, two complained of mild headache when
questioned the following day by telephone follow-up.
Both headaches resolved quickly with mild analgesics
(one with acetaminophen, the other with ibuprofen). A
further participant complained of nagging back pain, but
had suffered back pain for many years and the pain fol-
lowing the LP was not clearly different to pre-existing
pain. The duration for CSF extraction was a mean of 10
(range 5–23) minutes. A total of 16 mLs was taken from
all participants except one in whom only 11 mL was ex-
tracted because of slow gravity drip (22 minutes) during
which the participant became tired (see Table 3). All as-
piration samples were extracted in less than one minute.
Discussion
The current study confirms there is strong agreement in
CSF Aβ42, t-tau, and p-tau levels between gravity feed
and aspiration collection methods. Aβ42 and p-tau had
slightly lower concordance correlation coefficients (>0.8)
due to increased assay variation, causing a reduced
agreement statistic as compared with t-tau. Analyses of
the three biomarkers via paired samples t-tests showed
no significant difference between collection methods;
however, there was a trend towards a difference in p-tau
levels (largely driven by the AD group) prior to adjust-
ment for multiple comparisons. We included MCI and
AD controls to address the issue of varying HC levels of
AD pathology potentially influencing the dynamic levels
of each specific analyte or the way they behave ex vivo.
This is the first time to our knowledge that a direct
comparison of aspiration and gravity fed collection has
been reported.
Importantly, all CSF samples were taken sequentially
from the same LP and all analyzed simultaneously. The
CSF samples were thus not subjected to any variation in
pre-analytical handling other than the method of collec-
tion and, furthermore, were not exposed to technical
variations, which may have contributed to previously
seen variation observed between laboratories, underscor-
ing the accuracy of the results.
The method of CSF collection is an important step in
the pre-analytical handling of CSF samples. While some
investigators routinely use gravity, others use aspiration.
Gravity drip has the drawback of unpredictable variation
of collection times and may potentially take considerably
longer than aspiration, thereby reducing feasibility in
busy clinics. In dementia evaluation settings, the longer
duration of CSF acquisition can be a particular problem
for a patient with memory impairment or dementia
since repeated reassurance and explanation may be re-
quired. Our results demonstrate that syringe aspiration
does not have a significant effect on analyte concentra-
tions and, therefore, should be acceptable and allow pre-
dictable and more rapid CSF collection.
In our study, post lumbar puncture headaches using
the #27 and #25 gauge needles occurred in 2/54 proce-
dures (4 %) of patients consistent with previous reports
when using small caliber needles [14]. This is markedly
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Fig. 1 a-c Bland-Altman plots confirming good agreement between the two collection methods. d-f Concordance correlations between the
methodologies showed strong reproducibility for Aβ42, t-tau, and p-tau. g-i The median and interquartile range for each biomarker value divided
by each clinical classification (gravity = black; aspiration = grey)
Table 2 Mean values of AD CSF biomarkers, gravity versus aspiration
N Aβ42 [pg/mL] t-tau [pg/mL] p-tau [pg/mL]
g a p-value g a p-value g a p-value
Complete 44 366.5 (86.8) 354.3 (82.6) 0.10 83.9 (46.6) 84.7 (47.4) 0.49 43.5 (22.8) 40.0 (17.7) 0.05
HC 31 394.6 (56.4) 381.6 (65.8) 68.6 (27.9) 68.2 (28.8) 0.57 35.3 (12.1) 33.4 (11.5)
MCI 6 344.2 (73.5) 346.8 (55.7) 118.6 (65.1) 122.5 (68.6) 0.31 62.1 (28.9) 51.7 (18.4)
AD 7 261.38 (126.9) 240.04 (73.9) 121.92 (63.8) 125.27 (57.4) 0.58 63.86 (33.3) 59.08 (23.3)
Mean (standard deviation)
g gravity fed; a aspiration, t-tau total tau, p-tau phosphorylated-tau
p-values are unadjusted from Paired Sample T-tests
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below that reported when #24 or #22 Sprotte needles
are used (eg., 22 % [15]), but the mean age of their sam-
ples was 40.2 (10.1) years compared to the mean age of
our sample of 72.5 (5.5) years. Hence, an added bonus to
syringe aspiration is that negative pressure sampling al-
lows the use of small caliber spinal needles decreasing
the risk of headache. We emphasize that our results per-
tain to the use of small caliber spinal needles in an eld-
erly patient population. The use of larger caliber spinal
needles may lead to a higher incidence of headache, pre-
sumably due to more rapid shifts in CSF. Furthermore,
whilst gravity collection of CSF can take more than
20 minutes, aspiration can collect the usual 10–20 mLs
of CSF required in a few minutes.
Reasons for a preference of gravity flow collection over
aspiration in some centers may be historical. A belief
that aspiration may cause radicular pain by traumatizing
local nerve roots [16] appears unfounded, and might be
even less common with smaller caliber needles. On the
other hand, syringe aspiration may be inappropriate
whenever CSF pressure needs to be measured with man-
ometer tubing which then allows collection of tube con-
tents via gravity. Measurement of CSF opening pressure,
though, is not likely to be necessary when a CSF sample
is only required for the purpose of AD biomarker
analysis.
To our knowledge, this is the first report of concord-
ance of CSF biomarkers when CSF is collected either by
standard gravity drip or syringe aspiration. In particular,
more rapid collection by aspiration suggests that wider
adoption of aspiration is feasible and may become the
preferred means of CSF collection for the detection of
AD CSF profiles. Shorter duration should help facilitate
acceptance both by patients undergoing the procedure
and also staff conducting the LP. Indeed, the implica-
tions of reducing the time of the extraction of the CSF
from around ten minutes for gravity feed to approxi-
mately one minute for aspiration, may allow the proced-
ure to be suitable for mass screening as advocated by
Herskovits [5].
These results also indicate that the use of an extra
polypropylene contact step (in the syringe) used in the
aspiration technique made no significant difference to
the CSF biomarker concentrations, despite prior con-
cerns [17]. With the increasing use of atraumatic LP
needles, which dramatically reduce the incidence of
post-LP headache [18, 19], and the escalating need for
accurate diagnosis of early AD, our results add support
for aspiration as a time saving and benign method for
routine CSF collection for AD biomarker analyses.
A limitation to the study was that all aspirations were
performed subsequent to gravity drip collection. This
was because the protocol for the AIBL study demanded
that samples be taken by gravity drip, and, therefore, it
was only after the required samples had been obtained
for AIBL that we were able to take the aspiration sam-
ple. Although we consider it unlikely that reversing the
CSF collection technique order will significantly influ-
ence analyte concentrations, formal assessment of this
issue could be the subject of future studies.
A further limitation in this study was the relatively
small sample size, with varying proportions of variation
per analyte, and insufficient power to evaluate analyte
concordance within clinical classifications. Further stud-
ies with larger samples sizes are required to evaluate
whether clinical classification influences correlations be-
tween methods.
Conclusions
The results of this study indicate that there is no signifi-
cant difference in CSF AD biomarker concentrations for
Aβ42, p-tau, and total tau between gravity collection and
polypropylene syringe aspiration, yet aspiration is much
quicker. We conclude that aspiration should be con-
sidered as the favored collection technique for CSF AD
biomarker evaluation as this technique becomes more
widely adopted throughout the world.
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